Summit Therapeutics Inc. (NASDAQ:SMMT)
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$856.1M
- Net margin
- —
Little or no net debt.
- Total debt
- $20.4M
- Cash
- $419.4M
- Debt / equity
- 0.03
Comfortably covers what is due within a year.
- Current assets
- $720.6M
- Current liabilities
- $103.6M
- Current ratio
- 6.96
Consumes cash and must keep raising it.
- Operating cash flow
- -$405.4M
- Free cash flow
- -$406.7M
Heavy dilution — shareholders are paying for the business.
- Shares outstanding
- 778.2M
- Share growth (1y)
- 4.8%
- Cash runway
- 12 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
SMMT Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A Expense | 62.76 M | 62.59 M | 77.58 M | 103.11 M | 262.58 M | 12.06 M |
| R&D Expense | 157.73 M | 132.62 M | 147.29 M | 131.10 M | 151.56 M | 39.68 M |
| Operating Expenses | 220.50 M | 195.21 M | 224.88 M | 234.21 M | 414.14 M | 51.75 M |
| Operating Income | -220.50 M | -195.21 M | -224.88 M | -234.21 M | -414.14 M | -51.75 M |
| Pretax Income | -215.70 M | -189.42 M | -219.12 M | -231.79 M | -412.15 M | -48.70 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -215.70 M | -189.42 M | -219.17 M | -231.79 M | -412.15 M | -48.70 M |
| EPS (Basic) | -0.28 | -0.24 | -0.29 | -0.31 | -0.56 | -0.07 |
| EPS (Diluted) | -0.28 | -0.24 | -0.29 | -0.31 | -0.56 | -0.07 |
| Shares Outstanding | 778.18 M | 775.46 M | 766.40 M | 743.42 M | 742.61 M | 699.04 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.